Tempus publishes study validating the benefits of xf+, its comprehensive liquid biopsy assay for therapy selection

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced publication of its study, “analytical validation of ngs-based comprehensive liquid biopsy assay for therapy” in the journal of molecular diagnostics. data from this study supports the utility of xf+ as a non-invasive technique to detect actionable variants including resistance mutations, identify clinically relevant biomarkers,.
TEM Ratings Summary
TEM Quant Ranking